Tango Therapeutics (NASDAQ:TNGX – Get Free Report) had its target price lifted by equities research analysts at Guggenheim from $18.00 to $20.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 19.05% from the company’s current price. A […]

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) had its target price lifted by research analysts at Robert W. Baird from $14.00 to $20.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 44.82% from […]

Larimar Therapeutics (NASDAQ:LRMR – Free Report) had its target price raised by Wedbush from $11.00 to $12.00 in a research report report published on Tuesday morning, Marketbeat.com reports. Wedbush currently has an outperform rating on the stock. A number of other research firms have also recently commented on LRMR. Citigroup increased their target price on […]

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) had its price objective boosted by equities researchers at UBS Group from $2.00 to $4.00 in a report released on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s price objective suggests a potential downside of 7.41% from the stock’s previous […]

Vera Therapeutics (NASDAQ:VERA – Free Report) had its price target increased by HC Wainwright from $90.00 to $110.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a buy rating on the stock. A number of other research analysts also recently issued reports on VERA. Evercore boosted their price target on […]

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its target price boosted by investment analysts at Leerink Partners from $27.00 to $29.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ price target points to a potential upside of 110.22% from the stock’s current price. […]

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s share price was up 10.7% during trading on Monday after William Blair upgraded the stock from a market perform rating to an outperform rating. The stock traded as high as $15.35 and last traded at $15.2540. 9,385,176 shares traded hands during mid-day trading, an increase of 78% […]